Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Amgen Seeks U.K. Ban On Biosimilar Interchangeability With Innovator Product

Executive Summary

Amgen has won the support of several U.K. legislators who are advocating a ban on the automatic substitution of innovator biopharmaceuticals, but it appears unlikely the British government will impose such a prohibition

You may also be interested in...



Sandoz wins European approval of EPO biosimilar

The Novartis subsidiary's epoetin alfa follow-on Binocrit, which received European marketing approval Aug. 31, will be priced at a 25 to 30 percent discount to innovator products, Sandoz exec Ajaz Hussain tells "The Pink Sheet." The first launch will be in Germany in September. Sandoz is maintaining its lead in biosimilars; Binocrit is the first approval for biosimilar EPO, although positive opinions have been issued for products from Hexal Biotech Forschungs (another Novartis business unit) and Medice Arzneimittel Putter. Sandoz was first to market with a biosimilar human growth hormone, Omnitrope (1"The Pink Sheet" June 5, 2006, p. 3)...

Biosimilar “Interchangeability” Standard Is Double-Edged Sword For Generics

The interchangeability standard for follow-on biologics set out in Senate legislation creates a relatively smooth pathway for generic firms to seek approval of such products, but could also lead to an extended struggle to win acceptance for such products in the marketplace

COVID-19 Partnerships Without Formal Contracts Pose Risks, From Potential Liability To IP Issues

Companies are racing to co-develop coronavirus treatments before finalizing deal teams. These team-ups raise questions about what happens after the pandemic subsides.

UsernamePublicRestriction

Register

PS049277

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel